Pasithea has announced the commencement of a Phase I/Ib open-label trial of PAS-004 for treating adults with ...

ADC Therapeutics has pulled the drug candidate from development, leaving it with one remaining clinical asset.

Nuvig Therapeutics has dosed the first subject in its Phase II INVGOR trial of NVG-2089 for individuals with CIDP.

The trial aims to enrol roughly 420 NSCLC subjects who have undergone one to two previous therapy lines for advanced disease. Credit: create jobs 51/Shutterstock. Revolution Medicines has dosed the ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

Roche has reported overall survival outcomes from a Phase III trial of Perjeta with Herceptin and chemotherapy in early-stage ...

BridgeBio Pharma has dosed the first subject in the ACT-EARLY study of acoramidis, a drug intended to prevent transthyretin ...

People with bipolar disorder (BD) who have experienced childhood trauma (CT) will frequently document having more depressive ...

Connect Biopharma has begun a Phase II trial to assess rademikibart for treating acute exacerbations of asthma and type II ...

The EMA has approved Moleculin Biotech’s CTA for a Phase IIb/III trial of Annamycin plus cytarabine (Ara-C) for AML.

The human immunodeficiency virus (HIV) market across the seven major markets (7MM), comprising the US, France, Germany, Italy ...

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...